How does a COVID-19 vaccine make its way to market under an accelerated timeline?

Health

This scanning electron microscope image shows SARS-CoV-2 (yellow)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient in the U.S., emerging from the surface of cells (pink) cultured in the lab. Credit: NIAID-RML

Infectious disease specialist & Chief Medical Officer at Northwestern Medicine McHenry Hospital, Dr. Irfan Hafiz joins Roe Conn to discuss how an accelerated COVID-19 vaccine gets to market and the efficacy of a Harvard-led hydroxychloroquine -and a related form, chloroquine- study that found no benefits against coronavirus and increased the risk patients developing irregular heart rhythms and dying.

“Better knowledge means better health for you and your family. Turn to Northwestern Medicine at nm.org/healthbeatnews for health tips, research and more.”

Follow your favorite Roe Conn Show characters on Twitter:

And be sure to follow Roe on Facebook!

COVID-19 risk as determined by nonprofit Covid Act Now.

Coronavirus Resources from the CDC

Coronavirus by State

COVID-19 Testing Vs. Confirmed Cases by State

Interactive: Coronavirus Timeline

More Home Page Top Stories

Popular